| Literature DB >> 27717384 |
Matthias Heringlake1, Efstratios I Charitos2, Kira Erber3, Astrid Ellen Berggreen3, Hermann Heinze3, Hauke Paarmann4.
Abstract
BACKGROUND: Growth-differentiation factor-15 (GDF-15) is an emerging humoral marker for risk stratification in cardiovascular disease. Cardiac-surgery-associated acute kidney injury (CSA-AKI), an important complication in patients undergoing cardiac surgery, is associated with poor prognosis. The present secondary analysis of an observational cohort study aimed to determine the role of GDF-15 in predicting CSA-AKI compared with the Cleveland-Clinic Acute Renal Failure (CC-ARF) score and a logistic regression model including variables associated with renal dysfunction.Entities:
Keywords: Acute kidney injury; Biomarkers; Cardiac surgery; Cleveland Clinic Acute Renal Failure score; Euroscore; Growth-differentiation factor-15
Mesh:
Substances:
Year: 2016 PMID: 27717384 PMCID: PMC5055664 DOI: 10.1186/s13054-016-1482-3
Source DB: PubMed Journal: Crit Care ISSN: 1364-8535 Impact factor: 9.097
Demographics, preoperative, operative and postoperative characteristics of the patient population according to tertiles of preoperative growth-differentiation factor-15
| GDF tertile 1 | GDF tertile 2 | GDF tertile 3 | Total |
| |
|---|---|---|---|---|---|
|
| 392 | 392 | 392 | 1176 | |
| Male | 282 (71.9 %) | 272 (69.4 %) | 256 (65.3 %) | 810 (68.9 %) | 0.129 |
| Age (years) | 59 (50/67) | 69 (63/74) | 72 (67/77) | 68 (50/74) | <0.001 |
| NYHA I | 161 (41.1 %) | 137 (34.9 %) | 113 (28.8 %) | 411 (34.9 %) | 0.002 |
| NYHA II | 104 (26.5 %) | 97 (24.7 %) | 87 (22.2 %) | 288 (24.5 %) | 0.365 |
| NYHA III | 111 (28.3 %) | 138 (35.2 %) | 146 (37.2 %) | 395 (33.6 %) | 0.021 |
| NYHA IV | 15 (3.8 %) | 19 (4.8 %) | 44 (11.2 %) | 78 (6.6 %) | <0.001 |
| Additive Euroscore | 3 (2/6) | 5 (3/7) | 7 (5/8) | 5 (3/7) | <0.001 |
| GDF-15 (ng/ml) | 0.643 (0.535/0.730) | 0.991 (0.914/1.114) | 1.731 (1.438/2.329) | 0.989 (0.729/1.435) | <0.001 |
| NTproBNP (pg|ml) | 187.8 (74.4/495.0) | 427.9 (155.4/900.6) | 1044.6 (383.4/2528.7) | 434.5 (137.8/1139.3) | <0.001 |
| hsTNT (pg/ml) | 6.3 (3.0/11.1) | 11.4 (6.6/18.8) | 20.4 (12.0/38.0) | 11.4 (5.6/21.5) | <0.001 |
| ScO2minox (%) | 68 (63/72) | 65 (60/70) | 63 (57/67) | 65 (60/70) | <0.001 |
| Diabetes mellitus ( | 152 (38.8 %) | 250 (63.8 %) | 305 (77.8 %) | 707 (60.1 %) | <0.001 |
| LVEF 1 ( | 6 (1.5 %) | 10 (2.6 %) | 24 (6.1 %) | 40 (3.4 %) | <0.001 |
| LVEF 2 ( | 57 (14.5 %) | 74 (18.9 %) | 102 (26.0 %) | 233 (19.8 %) | <0.001 |
| LVEF 3 ( | 328 (36.4 %) | 307 (34.1 %) | 266 (29.5 %) | 901 (76.8 %) | <0.001 |
| Reoperation ( | 28 (7.1 %) | 35 (8.9 %) | 48 (12.2 %) | 111 (9.4 %) | 0.046 |
| Creatinine (μmol/l) | 73.9 (65.1/83.6) | 82.7 (68.6/93.3) | 93.3 (76.6/117.0) | 81.0 (68.6 /96.8) | <0.001 |
| eGFR (MDRD) (ml/min/m2) | 94.2 (80.1/110.5) | 80.7 (66.8/95.1) | 66.2 (49.5/83.4) | 80.9 (64.7/98.9)) | <0.001 |
| Hemoglobin (g/l) | 139 (130/148) | 135 (125/145) | 129 (115/140) | 135 (124/144) | <0.001 |
| Peripheral vascular disease ( | 45 (11.5 %) | 45 (11.5 %) | 47 (12.0 %) | 137 (11.6 %) | 0.967 |
| CPB time (minutes) | 108 (86/144) | 109 (84/135) | 114 (92/149) | 110 (88/142) | 0.027 |
| DHCA ( | 19 (4.8 %) | 8 (2.0 %) | 3 (0.8 %) | 30 (2.6 %) | 0.001 |
| IOP hemofiltration ( | 12 (3.0 %) | 12 (3.0 %) | 36 (9.2 %) | 60 (5.1 %) | <0.001 |
| Isolated CABG ( | 173 (44.1 %) | 199 (50.8 %) | 164 (41.8 %) | 536 (45.6 %) | 0.033 |
| Mitral valve surgery ( | 36 (9.2 %) | 55 (14.0 %) | 83 (21.2 %) | 174 (14.8 %) | <0.001 |
| Aortic valve surgery ( | 161 (41.1 %) | 133 (33.9 %) | 161 (41.1 %) | 455 (38.7 %) | 0.06 |
| MAZE ( | 19 (4.8 %) | 31 (7.9 %) | 53 (13.5 %) | 103 | <0.001 |
| HDU LOS (days) | 2 (2/4) | 3 (2/5) | 4 (2/7) | 3 (2/5) | <0.001 |
| AKI 1 | 37 (9.4 %) | 53 (13.5 %) | 85 (21.7 %) | 175 (14.9 %) | <0.001 |
| AKI 2 | 3 (0.76 %) | 1 (0.26 %) | 2 (0.51 %) | 6 (0.51 %) | 0.65 |
| AKI 3 | 4 (1.0 %) | 17 (4.3 %) | 56 (14.3 %) | 77 (6.54 %) | <0.001 |
| Renal replacement therapy | 4 (1 %) | 17 (4.3 %) | 55 (14.3 %) | 77 (6.45 %) | <0.001 |
| 30-day mortality | 2 (0.5 %) | 4 (1 %) | 17 (4.4 %) | 23 (1.96 %) | <0.001 |
NYHA New York Heart Association grade of heart failure, NTproBNP N-terminal pro-hormone of the B-type natriuretic peptide, hsTNT high-sensitivity troponine-T, LVEF left ventricular ejection fraction (1: <30 % or severely reduced; 2: 30–50 % or moderately reduced; 3: ≥50 % or normal), MDRD creatinine clearance according to the Modifications of Diet in Renal Disease formula, CPB cardiopulmonary bypass time, DHCA deep hypothermic circulatory arrest, IOP-hemofiltration intraoperative hemofiltration during CPB, CABG coronary artery bypass graft, MAZE MAZE - procedure; HDU LOS high-dependency unit time (intensive care and intermediate care unit), AKI 1 to AKI 3 acute kidney injury according to KDIGO creatinine criteria
Fig. 1Plasma growth-differentiation factor-15 (GDF-15) in patients without acute kidney injury (AKI) and in patients with AKI grade 1 (AKI-1) and grade 3: *analysis of variance; p < 0.001). Preoperative plasma GDF-15 was significantly higher in relation to the severity of AKI in comparison with patients without this complication (no AKI vs. Grade 1, p < 0.001; Grade 1 vs Grade 3, p < 0.001)
Final logistic regression model specification for any grade of acute kidney injury
| Factor | Odds ratio | 95 % CI |
| Bootstrap reliability |
|---|---|---|---|---|
| Intercept | 0.002 | 0.0006, 0.007 | <0.001 | 99.8 % |
| GDF-15 (ng/ml) | 1.314 | 1.142, 1.551 | <0.001 | 95.4 % |
| Age (years) | 1.039 | 1.021, 1.058 | <0.001 | 98.9 % |
| Additive Euroscore | 1.074 | 1.009, 1.143 | 0.02 | 71.3 % |
| Creatinine (μmol/l) | 1.007 | 1.002, 1.011 | 0.003 | 79.0 % |
| Diabetes mellitus | 1.362 | 0.981, 1.881 | 0.06 | 50.1 % |
| CPB time (minutes) | 1.006 | 1.003, 1.009 | <0.001 | 96.6 % |
For any increase in growth-differentiation factor-15 (GDF-15) of 1 ng/ml the odds ratio for developing acute kidney injury of is 1.34. CPB cardiopulmonary bypass
Fig. 2Probability of a prototypical patient aged 65 years with an additive Euroscore of 5.15, and a duration of cardiopulmonary bypass of 123 minutes for a range of creatinine values (x-axis) and the 5 and 95 % quantiles of growth-differentiation factor-15 (GDF-15) (0.467 and 2.770, respectively) as derived from the multivariate model. AKI acute kidney injury, CC-ARF Cleveland Clinic Acute Renal Failure (score)
Fig. 3Receiver operator characteristics of the Cleveland clinic acute renal failure (CC-ARF) score [13] and nested logistic regression models on the development of cardiac-surgery-associated acute kidney injury (CSA-AKI) with and without taking into account preoperative plasma levels of growth-differentiation factor-15 (GDF). a Analyses for any stage of AKI (i.e., AKI-1 to AKI-3). b Analysis restricted AKI-3 only. The inclusion of GDF in the models led to statistically significant (analysis of variance; p < 0.001) predictive ability (either CC-ARF or a model based on additive Euroscore, age, plasma creatinine, diabetes mellitus, and duration of cardiopulmonary bypass). AUC area under the curve
Fig. 4Receiver operator characteristics of nested logistic regression models on the development of cardiac-surgery-associated acute kidney injury (CSA-AKI) with and without (w/o) taking into account preoperative plasma levels of growth-differentiation factor-15 (GDF) for acute kidney injury (AKI) grade 1 and 3. While the inclusion of GDF led to a statistically significant increase in the area under curve (AUC) for AKI grade 3, this was not the case for AKI grade 1
Reclassification analysis
| Outcome: absent | |||||
| Updated model (risk categories) | |||||
| Initial model (risk categories) | (0, 0.01) | (0.01, 0.05) | (0.05, 0.1) | (0.1, 1) | % reclassified |
| (0, 0.01) | 0 | 0 | 0 | 0 | - |
| (0.01, 0.05) | 0 | 53 | 2 | 0 | 4 |
| (0.05, 0.1) | 0 | 12 | 143 | 13 | 15 |
| (0.1, 1) 0 | 0 | 24 | 669 | 3 | |
| Outcome: present | |||||
| Updated model (risk categories) | |||||
| Initial model (risk categories) | (0, 0.01) | (0.01, 0.05) | (0.05, 0.1) | (0.1, 1) | % reclassified |
| (0, 0.01) | 0 | 0 | 0 | 0 | - |
| (0.01, 0.05) | 0 | 4 | 1 | 0 | 20 |
| (0.05, 0.1) | 0 | 1 | 16 | 1 | 11 |
| (0.1, 1) | 0 | 0 | 1 | 233 | 0 |
| Combined data | |||||
| Updated model (risk categories) | |||||
| Initial model (risk categories) | (0, 0.01) | (0.01, 0.05) | (0.05, 0.1) | (0.1, 1) | % reclassified |
| (0, 0.01) | 0 | 0 | 0 | 0 | - |
| (0.01, 0.05) | 0 | 57 | 3 | 0 | 5 |
| (0.05, 0.1) | 0 | 13 | 159 | 14 | 15 |
| (0.1, 1) | 0 | 0 | 25 | 902 | 3 |
Net-reclassification improvement (NRI) (categorical) (95 % CI): 0.0229 (0.0014, 0.0445); p value 0.03697. NRI (continuous) (95 % CI): 0.308 (0.1739, 0.4421); p value: 0.00001. Integrated discrimination improvement (95 % CI): 0.015 (0.006, 0.024); p value: 0.00107. Reclassification table of the model without (initial) and with (updated) growth-differentiation factor-15 (GDF-15) as a predictor of cardiac-surgery-associated acute kidney injury (CSA-AKI). The addition of GDF-15 in the logistic regression model significantly improved prediction of the development of CSA-AKI.
Fig. 5Recursive partitioning using conditional inference trees. Starting from the top, important variables and their respective cutoffs are presented leading (bottom) to the percentage of patients (within each population partition) developing cardiac-surgery-associated acute kidney injury (CSA-AKI). For example, from the group of patients with additive Euroscore <5 and growth-differentiation factor-15 (GDF-15) <1.271 ng/ml, 10 % developed CSA-AKI (Node 3), whereas from the group of patients with additive Euroscore <5 and GDF-15 > 1.271 ng/ml, 20 % of patients developed CSA-AKI (Node 4). CPB cardiopulmonary bypass